Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule

A. Biroccio, D. Del Bufalo, A. Ricca, C. D'Angelo, G. D'Orazi, A. Sacchi, S. Soddu, G. Zupi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In this article, we investigated the effect induced by the reintroduction of wild-type p53 (wt-p53) protein on BCNU sensitivity in the ADF glioblastoma line. Using a wt-p53 recombinant adenovirus (Ad-p53), we demonstrated that exogenous wt-p53 expression was able to increase the sensitivity to BCNU in ADF cells. Interestingly, this effect was more evident when Ad-p53 infection was performed after BCNU treatment compared with the opposite sequence. To understand the biological basis of these different behaviors, we analyzed the cell cycle of the differently treated cells. We found that Ad-p53 infection induced a persistent accumulation of cells in the G0/G1 phase while, as expected, BCNU induced a block in the G2-M phase. Ad-p53→BCNU sequence did not significantly modify the cell cycle profile in respect of Ad-p53 infected cells. In contrast, BCNU→Ad-p53 sequence provoked G2-M arrest similar to that observed after treatment with BCNU alone, but prevented the later recovery of the cells through the cell cycle, by driving the cells to apoptotic death. These results demonstrate that the administration sequence is important to increase drug sensitivity. To generalize the phenomenon observed in ADF line, the antiproliferative effect of the two different schedules was analyzed on other glioblastoma lines (A172, CRS-A2, U373MG) with different BCNU sensitivity and p53 status. The data obtained confirm that the wt-p53 gene transfer enhances BCNU sensitivity in glioblastoma cells depending on the administration sequence.

Original languageEnglish
Pages (from-to)1064-1072
Number of pages9
JournalGene Therapy
Volume6
Issue number6
DOIs
Publication statusPublished - 1999

Fingerprint

Carmustine
p53 Genes
Glioblastoma
Genetic Therapy
Appointments and Schedules
Cell Cycle
Cell Cycle Resting Phase
G2 Phase
G1 Phase
Infection
varespladib methyl
Adenoviridae
Cell Division
Therapeutics
Pharmaceutical Preparations

Keywords

  • BCNU
  • Gene therapy
  • Glioblastoma
  • wt-p53

ASJC Scopus subject areas

  • Genetics

Cite this

Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. / Biroccio, A.; Del Bufalo, D.; Ricca, A.; D'Angelo, C.; D'Orazi, G.; Sacchi, A.; Soddu, S.; Zupi, G.

In: Gene Therapy, Vol. 6, No. 6, 1999, p. 1064-1072.

Research output: Contribution to journalArticle

@article{47ee508891da4aad9f1cf3986fa1aef2,
title = "Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule",
abstract = "In this article, we investigated the effect induced by the reintroduction of wild-type p53 (wt-p53) protein on BCNU sensitivity in the ADF glioblastoma line. Using a wt-p53 recombinant adenovirus (Ad-p53), we demonstrated that exogenous wt-p53 expression was able to increase the sensitivity to BCNU in ADF cells. Interestingly, this effect was more evident when Ad-p53 infection was performed after BCNU treatment compared with the opposite sequence. To understand the biological basis of these different behaviors, we analyzed the cell cycle of the differently treated cells. We found that Ad-p53 infection induced a persistent accumulation of cells in the G0/G1 phase while, as expected, BCNU induced a block in the G2-M phase. Ad-p53→BCNU sequence did not significantly modify the cell cycle profile in respect of Ad-p53 infected cells. In contrast, BCNU→Ad-p53 sequence provoked G2-M arrest similar to that observed after treatment with BCNU alone, but prevented the later recovery of the cells through the cell cycle, by driving the cells to apoptotic death. These results demonstrate that the administration sequence is important to increase drug sensitivity. To generalize the phenomenon observed in ADF line, the antiproliferative effect of the two different schedules was analyzed on other glioblastoma lines (A172, CRS-A2, U373MG) with different BCNU sensitivity and p53 status. The data obtained confirm that the wt-p53 gene transfer enhances BCNU sensitivity in glioblastoma cells depending on the administration sequence.",
keywords = "BCNU, Gene therapy, Glioblastoma, wt-p53",
author = "A. Biroccio and {Del Bufalo}, D. and A. Ricca and C. D'Angelo and G. D'Orazi and A. Sacchi and S. Soddu and G. Zupi",
year = "1999",
doi = "10.1038/sj.gt.3300935",
language = "English",
volume = "6",
pages = "1064--1072",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule

AU - Biroccio, A.

AU - Del Bufalo, D.

AU - Ricca, A.

AU - D'Angelo, C.

AU - D'Orazi, G.

AU - Sacchi, A.

AU - Soddu, S.

AU - Zupi, G.

PY - 1999

Y1 - 1999

N2 - In this article, we investigated the effect induced by the reintroduction of wild-type p53 (wt-p53) protein on BCNU sensitivity in the ADF glioblastoma line. Using a wt-p53 recombinant adenovirus (Ad-p53), we demonstrated that exogenous wt-p53 expression was able to increase the sensitivity to BCNU in ADF cells. Interestingly, this effect was more evident when Ad-p53 infection was performed after BCNU treatment compared with the opposite sequence. To understand the biological basis of these different behaviors, we analyzed the cell cycle of the differently treated cells. We found that Ad-p53 infection induced a persistent accumulation of cells in the G0/G1 phase while, as expected, BCNU induced a block in the G2-M phase. Ad-p53→BCNU sequence did not significantly modify the cell cycle profile in respect of Ad-p53 infected cells. In contrast, BCNU→Ad-p53 sequence provoked G2-M arrest similar to that observed after treatment with BCNU alone, but prevented the later recovery of the cells through the cell cycle, by driving the cells to apoptotic death. These results demonstrate that the administration sequence is important to increase drug sensitivity. To generalize the phenomenon observed in ADF line, the antiproliferative effect of the two different schedules was analyzed on other glioblastoma lines (A172, CRS-A2, U373MG) with different BCNU sensitivity and p53 status. The data obtained confirm that the wt-p53 gene transfer enhances BCNU sensitivity in glioblastoma cells depending on the administration sequence.

AB - In this article, we investigated the effect induced by the reintroduction of wild-type p53 (wt-p53) protein on BCNU sensitivity in the ADF glioblastoma line. Using a wt-p53 recombinant adenovirus (Ad-p53), we demonstrated that exogenous wt-p53 expression was able to increase the sensitivity to BCNU in ADF cells. Interestingly, this effect was more evident when Ad-p53 infection was performed after BCNU treatment compared with the opposite sequence. To understand the biological basis of these different behaviors, we analyzed the cell cycle of the differently treated cells. We found that Ad-p53 infection induced a persistent accumulation of cells in the G0/G1 phase while, as expected, BCNU induced a block in the G2-M phase. Ad-p53→BCNU sequence did not significantly modify the cell cycle profile in respect of Ad-p53 infected cells. In contrast, BCNU→Ad-p53 sequence provoked G2-M arrest similar to that observed after treatment with BCNU alone, but prevented the later recovery of the cells through the cell cycle, by driving the cells to apoptotic death. These results demonstrate that the administration sequence is important to increase drug sensitivity. To generalize the phenomenon observed in ADF line, the antiproliferative effect of the two different schedules was analyzed on other glioblastoma lines (A172, CRS-A2, U373MG) with different BCNU sensitivity and p53 status. The data obtained confirm that the wt-p53 gene transfer enhances BCNU sensitivity in glioblastoma cells depending on the administration sequence.

KW - BCNU

KW - Gene therapy

KW - Glioblastoma

KW - wt-p53

UR - http://www.scopus.com/inward/record.url?scp=0033058950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033058950&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3300935

DO - 10.1038/sj.gt.3300935

M3 - Article

VL - 6

SP - 1064

EP - 1072

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -